Market
Aug 15, 2025
After a productive year at EPFL, Bioscibex has moved to BioArk in Monthey to support its next growth phase. With its proof of concept validated and three MVPs ready, the startup is preparing for its first industrial-scale customer demonstrations and gearing up for commercial launch.
After a highly supportive and productive year at the Protein Production and Structure Core Facility at EPFL, led by Dr. Florence Pojer, Bioscibex has recently relocated to the BioArk site in Monthey, Switzerland. There, the company will benefit from a dynamic life sciences ecosystem designed to support its growth.
With its proof of concept now validated and three minimum viable products (MVPs) ready, the startup is preparing to initiate its first customer demonstrations. “This step is essential to validate the technology at industrial scale ahead of commercialization,” comments Chloé Albietz.
Bioscibex is currently concentrating on two key priorities: finalizing the industrialization of its bioreactor and consumables, and preparing for market entry.
In parallel, the company plans to strengthen its team with the recruitment of a field application specialist to support upcoming customer demonstrations.
Bioscibex has joined BioArk, an innovation-driven ecosystem dedicated to life sciences, and is also part of The Ark Foundation’s startup incubator, which provides technical and commercial support to accelerate the development of its innovation.
